CAREDX, INC. (CDNA) Spending and interest coverage
- R&D / revenue · 12 months: Value 17.43%; Formula and calculation Research and development expense / revenue. Period ending 2026-06-30..
- Stock-based compensation / revenue · 12 months: Value 8.07%; Formula and calculation Share-based compensation / revenue. Period ending 2026-06-30..
- Interest coverage · 12 months: Value (m); Formula and calculation Estimated: average term debt × dated USD coupon proxy + average commercial paper × matching-currency disclosed rate at or before period end. Swaps, foreign-exchange, lease interest and amortization are not quantified..
Spending and interest coverage
Overview →Financial period ending 2026-06-30; current quote (m). Amounts retain their stated periods and units.
| Metric | Value | Formula and calculation |
|---|---|---|
| R&D / revenue · 12 months | 17.43% | Research and development expense / revenue. Period ending 2026-06-30. $79.87M ÷ $458.09M × 100 ≈ 17.43% |
| Stock-based compensation / revenue · 12 months | 8.07% | Share-based compensation / revenue. Period ending 2026-06-30. $36.97M ÷ $458.09M × 100 ≈ 8.07% |
| Interest coverage · 12 months | (m) | Estimated: average term debt × dated USD coupon proxy + average commercial paper × matching-currency disclosed rate at or before period end. Swaps, foreign-exchange, lease interest and amortization are not quantified. Calculation unavailable: missing inputs remain (m). |
Calculation inputs
| Input | Amount with unit | Raw financial data |
|---|---|---|
| Research and development spending | 79.87M USD | Research and Development Expense |
| Revenue | 458.09M USD | Revenue from Contract with Customer, Excluding Assessed Tax |
| Stock-based compensation | 36.97M USD | Share-based Payment Arrangement, Noncash Expense |
| Operating income | 108.14M USD | Operating Income (Loss) |
| Interest expense · reported / estimated | (m) | Interest Expense · Estimated expense assumptions |
Latest interest expense basis: (m). Estimated values carry *; expand each history row’s basis for its dated balances and rate assumptions.
Calculated history
Changes compare with the next older row (previous quarter), unless explicitly labeled otherwise. Rolling 12-month growth compares two successive quarter-end rolling totals; it is not year-over-year growth.
| Period ending | Research and development spending (USD) | Revenue (USD) | Stock-based compensation (USD) | Operating income (USD) | Interest expense · reported / estimated (USD) | R&D / revenue | SBC / revenue | Interest coverage | Interest expense basis |
|---|---|---|---|---|---|---|---|---|---|
| 2026-06-30 | $79.87M | $458.09M | $36.97M | $108.14M | (m) | 17.43% | 8.07% | (m) | (m) |
| 2026-03-31 | $74.32M | $412.82M | $35.74M | $-16.21M | (m) | 18.00% | 8.66% | (m) | (m) |
| 2025-12-31 | $71.43M | $379.81M | $34.86M | $-30.78M | (m) | 18.81% | 9.18% | (m) | (m) |
| 2025-09-30 | $68.64M | $358.00M | $43.28M | $59.64M | (m) | 19.17% | 12.09% | (m) | (m) |
| 2025-06-30 | $69.36M | $340.83M | $51.79M | $46.16M | (m) | 20.35% | 15.20% | (m) | (m) |
| 2025-03-31 | $72.22M | $346.42M | $58.76M | $49.96M | (m) | 20.85% | 16.96% | (m) | (m) |
| 2024-12-31 | $72.41M | $333.79M | $66.41M | $40.77M | (m) | 21.69% | 19.89% | (m) | (m) |
| 2024-09-30 | $74.15M | $312.77M | $50.17M | $-156.56M | (m) | 23.71% | 16.04% | (m) | (m) |
| 2024-06-30 | $75.67M | $297.08M | $49.15M | $-174.85M | (m) | 25.47% | 16.54% | (m) | (m) |
| 2024-03-31 | $76.22M | $275.11M | $48.68M | $-198.38M | (m) | 27.71% | 17.69% | (m) | (m) |
| 2023-12-31 | $81.87M | $280.32M | $49.09M | $-203.36M | (m) | 29.20% | 17.51% | (m) | (m) |
| 2023-09-30 | $87.16M | $297.14M | $51.25M | $-99.85M | (m) | 29.33% | 17.25% | (m) | (m) |
| 2023-06-30 | $90.47M | $309.31M | $49.78M | $-88.41M | (m) | 29.25% | 16.09% | (m) | (m) |
| 2023-03-31 | $92.86M | $319.64M | $49.67M | $-82.50M | (m) | 29.05% | 15.54% | (m) | (m) |
| 2022-12-31 | $90.39M | $321.79M | $46.55M | $-77.23M | (m) | 28.09% | 14.47% | (m) | (m) |
| 2022-09-30 | $88.86M | $318.63M | $43.92M | $-73.51M | (m) | 27.89% | 13.79% | (m) | (m) |
| 2022-06-30 | $86.00M | $314.86M | $43.36M | $-64.90M | (m) | 27.31% | 13.77% | (m) | (m) |
| 2022-03-31 | $82.40M | $308.41M | $40.17M | $-47.92M | (m) | 26.72% | 13.02% | (m) | (m) |
| 2021-12-31 | $76.53M | $296.40M | $36.08M | $-29.73M | (m) | 25.82% | 12.17% | (m) | (m) |
| 2021-09-30 | $67.80M | $275.82M | $32.56M | $-17.39M | (m) | 24.58% | 11.80% | (m) | (m) |
| 2021-06-30 | $60.84M | $253.60M | $28.67M | $-11.57M | (m) | 23.99% | 11.31% | (m) | (m) |
| 2021-03-31 | $54.93M | $221.21M | $25.69M | $-17.64M | (m) | 24.83% | 11.61% | (m) | (m) |
| 2020-12-31 | $48.94M | $192.19M | $23.40M | $-22.53M | (m) | 25.46% | 12.18% | (m) | (m) |
| 2020-09-30 | $44.56M | $169.37M | $22.83M | $-25.01M | (m) | 26.31% | 13.48% | (m) | (m) |
| 2020-06-30 | $40.61M | $149.81M | $22.05M | $-28.85M | (m) | 27.11% | 14.72% | (m) | (m) |
| 2020-03-31 | $35.11M | $139.47M | $20.62M | $-24.89M | (m) | 25.17% | 14.79% | (m) | (m) |
| 2019-12-31 | $30.71M | $127.07M | $22.42M | $-24.53M | (m) | 24.17% | 17.64% | (m) | (m) |
| 2019-09-30 | $25.55M | $114.76M | $19.07M | $-21.40M | (m) | 22.26% | 16.62% | (m) | (m) |
| 2019-06-30 | $20.89M | $102.13M | $14.97M | $-17.37M | (m) | 20.46% | 14.65% | (m) | (m) |
| 2019-03-31 | $16.76M | $88.50M | $12.48M | $-15.74M | (m) | 18.94% | 14.11% | (m) | (m) |
| 2018-12-31 | $14.51M | $76.57M | $7.14M | $-15.58M | (m) | 18.96% | 9.32% | (m) | (m) |
| 2018-09-30 | $13.76M | $65.56M | $5.51M | $-17.45M | (m) | 20.99% | 8.40% | (m) | (m) |
| 2018-06-30 | $12.85M | $56.57M | $4.08M | $-18.59M | (m) | 22.72% | 7.20% | (m) | (m) |
| 2018-03-31 | $12.47M | $50.79M | $2.06M | $-16.98M | (m) | 24.56% | 4.05% | (m) | (m) |
| 2017-12-31 | $12.39M | $48.32M | $1.74M | $-20.29M | (m) | 25.64% | 3.61% | (m) | (m) |
| 2017-09-30 | $12.51M | $46.68M | $1.80M | $-34.87M | (m) | 26.81% | 3.86% | (m) | (m) |
| 2017-06-30 | $12.48M | $46.96M | $2.07M | $-35.94M | (m) | 26.58% | 4.41% | (m) | (m) |
| 2017-03-31 | $12.51M | $45.65M | $1.94M | $-39.31M | (m) | 27.40% | 4.26% | (m) | (m) |
| 2016-12-31 | $12.38M | $40.63M | $2.00M | $-37.33M | (m) | 30.48% | 4.92% | (m) | (m) |
| 2016-09-30 | $11.94M | $36.42M | $1.82M | $-22.93M | (m) | 32.77% | 5.01% | (m) | (m) |
| 2016-06-30 | $11.70M | $31.10M | $1.46M | $-21.19M | (m) | 37.64% | 4.70% | (m) | (m) |
| 2016-03-31 | $11.07M | $27.49M | $1.51M | $-17.11M | (m) | 40.27% | 5.48% | (m) | (m) |
| 2015-12-31 | $9.33M | $28.14M | $1.34M | $-11.93M | (m) | 33.16% | 4.76% | (m) | (m) |
| 2015-09-30 | $7.93M | $29.45M | $1.21M | $-7.04M | (m) | 26.92% | 4.12% | (m) | (m) |
| 2015-06-30 | $6.26M | $28.95M | $1.04M | $-2.46M | (m) | 21.64% | 3.60% | (m) | (m) |
| 2015-03-31 | $4.55M | $28.60M | $767.00K | $86.00K | (m) | 15.90% | 2.68% | (m) | (m) |
| 2014-12-31 | $3.85M | $27.31M | $535.00K | $1.25M | (m) | 14.08% | 1.96% | (m) | (m) |
| 2014-09-30 | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) |
| 2014-06-30 | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) |
| 2014-03-31 | (m) | $23.04M | (m) | (m) | (m) | (m) | (m) | (m) | (m) |
| 2013-12-31 | $3.18M | $22.10M | $72.00K | $-857.00K | (m) | 14.37% | 0.33% | (m) | (m) |
| 2013-09-30 | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) |
| 2013-06-30 | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) |
| 2012-12-31 | $4.75M | $20.45M | $69.00K | $-2.34M | (m) | 23.24% | 0.34% | (m) | (m) |
(m) means missing inputs. Historical market-based ratios use the saved close on or immediately before period ending and that period’s reported shares; current quotes are not substituted. Five-year projections repeat historical CAGR, not analyst forecasts.
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Celcuity Inc. (CELC) | United States | $3.887B | -22.62 |
| VERACYTE, INC. (VCYT) | United States | $3.904B | 41.21 |
| Fortrea Holdings Inc. (FTRE) | United States | $1.903B | -19.43 |
| Personalis, Inc. (PSNL) | United States | $1.769B | -13.30 |
| CASTLE BIOSCIENCES INC (CSTL) | United States | $1.074B | -37.45 |
| Lumexa Imaging Holdings, Inc. (LMRI) | United States | $0.951B | |
| GRAIL, Inc. (GRAL) | United States | $5.591B | -7.78 |
| RadNet, Inc. (RDNT) | United States | $5.611B | -229.65 |
| Fulgent Genetics, Inc. (FLGT) | United States | $0.593B | -6.70 |
| BIODESIX INC (BDSX) | United States | $0.312B |